[HTML][HTML] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS^
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - ncbi.nlm.nih.gov
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - europepmc.org
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
[引用][C] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
EJM Bertrums, CM Zwaan, D Hasegawa, V de Haas… - Haematologica, 2022 - pure.au.dk
Guideline for management of non-Down syndrome neonates with a myeloproliferative
disease on behalf of the I-BFM AML Study Group and EWOG-MDS — Aarhus University …
disease on behalf of the I-BFM AML Study Group and EWOG-MDS — Aarhus University …
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on
behalf of the I-BFM AML Study Group and EWOG-MDS Guideline for management of non-Down …
behalf of the I-BFM AML Study Group and EWOG-MDS Guideline for management of non-Down …
[HTML][HTML] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - haematologica.org
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
[PDF][PDF] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
Haematologica, 2021 - academia.edu
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease
on behalf of the I-BFM AML Study Grou Page 1 Guideline for management of non-Down …
on behalf of the I-BFM AML Study Grou Page 1 Guideline for management of non-Down …
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BMF AML Study Group and EWOG-MDS
E Bertrums, CM Zwaan, D Hasegawa, V de Haas… - …, 2022 - biblio.ugent.be
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - publicatt.unicatt.it
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease
on behalf of the I-BFM AML Study Group and EWOG-MDS IRIS IRIS Home Sfoglia …
on behalf of the I-BFM AML Study Group and EWOG-MDS IRIS IRIS Home Sfoglia …
[HTML][HTML] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - haematologica.org
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.
EJM Bertrums, CM Zwaan, D Hasegawa… - …, 2022 - europepmc.org
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …
(DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and …